1-3 of 3
Roberto Chiarle
Close
Sort by
Journal Articles

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK + lymphomas

Giovanni Rindone, Andrea Aroldi, Elisa Bossi, Luisa Verga, Giovanni Zambrotta, Sara Tarantino, Rocco Piazza, Lara Mussolin, Roberto Chiarle, Carlo Gambacorti-Passerini
Journal: Blood Advances
Blood Adv (2023) 7 (3): 314–316.
https://doi.org/10.1182/bloodadvances.2022007538
Published: 2023
Includes: Supplemental data
Journal Articles

Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn

Rahela Aziz-Bose, Franziska Wachter, Roberto Chiarle, Neal I. Lindeman, Annette S. Kim, Barbara A. Degar, Kimberly Davies, Yana Pikman
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2893–2896.
https://doi.org/10.1182/bloodadvances.2021006865
Published: 2022
Journal Articles

Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma

Chiara Pighi, Taek-Chin Cheong, Mara Compagno, Enrico Patrucco, Maddalena Arigoni, Martina Olivero, Qi Wang, Cristina López, Stephan H. Bernhart, Bruno M. Grande, Teresa Poggio, Fernanda Langellotto, Lisa Bonello, Riccardo Dall’Olio, Sandra Martínez-Martín, Luca Molinaro, Paola Francia di Celle, Jonathan R. Whitfield, Laura Soucek, Claudia Voena, Raffaele A. Calogero, Ryan D. Morin, Louis M. Staudt, Reiner Siebert, Alberto Zamò, Roberto Chiarle
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5239–5257.
https://doi.org/10.1182/bloodadvances.2021005682
Published: 2021
Includes: Supplemental data